Pharmaceutical manufacturers may be able to do away with dedicated cardiovascular outcomes trials (CVOTs) for new type 2 diabetes drugs, but it would come at the cost of having to conduct longer and more extensive Phase II/III studies that provide reassurance about CV safety, US FDA advisory committee members said Oct. 25.
Longer premarketing trials that enroll broader patient populations and focus on a broader variety of endpoints beyond glucose control, such...





